595 related articles for article (PubMed ID: 9423160)
1. Physicochemical characterization of nedocromil bivalent metal salt hydrates. 3. Nedocromil calcium.
Zhu H; Halfen JA; Young VG; Padden BE; Munson EJ; Menon V; Grant DJ
J Pharm Sci; 1997 Dec; 86(12):1439-47. PubMed ID: 9423160
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical characterization of nedocromil bivalent metal salt hydrates. 2. Nedocromil zinc.
Zhu H; Padden BE; Munson EJ; Grant DJ
J Pharm Sci; 1997 Apr; 86(4):418-29. PubMed ID: 9109042
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical characterization of nedocromil bivalent metal salt hydrates. 1. Nedocromil magnesium.
Zhu H; Khankari RK; Padden BE; Munson EJ; Gleason WB; Grant DJ
J Pharm Sci; 1996 Oct; 85(10):1026-34. PubMed ID: 8897266
[TBL] [Abstract][Full Text] [Related]
4. Physical characterization of nedocromil sodium hydrates.
Khankari R; Chen L; Grant DJ
J Pharm Sci; 1998 Sep; 87(9):1052-61. PubMed ID: 9724554
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical characterization of the various solid forms of carbovir, an antiviral nucleoside.
Nguyen NA; Ghosh S; Gatlin LA; Grant DJ
J Pharm Sci; 1994 Aug; 83(8):1116-23. PubMed ID: 7983595
[TBL] [Abstract][Full Text] [Related]
6. Dehydration behavior of nedocromil magnesium pentahydrate.
Zhu H; Grant DJ
Int J Pharm; 2001 Mar; 215(1-2):251-62. PubMed ID: 11250110
[TBL] [Abstract][Full Text] [Related]
7. A study of variable hydration states in topotecan hydrochloride.
Vogt FG; Dell'Orco PC; Diederich AM; Su Q; Wood JL; Zuber GE; Katrincic LM; Mueller RL; Busby DJ; Debrosse CW
J Pharm Biomed Anal; 2006 Mar; 40(5):1080-8. PubMed ID: 16242889
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of stoichiometric and nonstoichiometric hydrate forms of paroxetine HCl: reversible changes in crystal dimensions as a function of water absorption.
Pina MF; Pinto JF; Sousa JJ; Fábián L; Zhao M; Craig DQ
Mol Pharm; 2012 Dec; 9(12):3515-25. PubMed ID: 23051151
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure and thermal behavior of nedocromil nickel octahydrate.
Zhu HJ; Young VG; Grant DJ
Int J Pharm; 2002 Jan; 232(1-2):23-33. PubMed ID: 11790487
[TBL] [Abstract][Full Text] [Related]
10. Solid-state characterization of two polymorphs of aspartame hemihydrate.
Leung SS; Padden BE; Munson EJ; Grant DJ
J Pharm Sci; 1998 Apr; 87(4):501-7. PubMed ID: 9548905
[TBL] [Abstract][Full Text] [Related]
11. Nuclear magnetic resonance and infrared spectroscopic analysis of nedocromil hydrates.
Chen LR; Padden BE; Vippagunta SR; Munson EJ; Grant DJ
Pharm Res; 2000 May; 17(5):619-24. PubMed ID: 10888316
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical characterization of a new respirable form of nedocromil.
Chan HK; Gonda I
J Pharm Sci; 1995 Jun; 84(6):692-6. PubMed ID: 7562406
[TBL] [Abstract][Full Text] [Related]
13. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
14. Coordination of biologically important alpha-amino acids to calcium(II) at high pH: insights from crystal structures of calcium alpha-aminocarboxylates.
Fox S; Büsching I; Barklage W; Strasdeit H
Inorg Chem; 2007 Feb; 46(3):818-24. PubMed ID: 17257025
[TBL] [Abstract][Full Text] [Related]
15. Solid-state characterization and dissolution properties of Fluvastatin sodium salt hydrates.
Borgmann SH; Bernardi LS; Rauber GS; Oliveira PR; Campos CE; Monti G; Cuffini SL; Cardoso SG
Pharm Dev Technol; 2013; 18(2):525-34. PubMed ID: 23033850
[TBL] [Abstract][Full Text] [Related]
16. Solid-State Characterization of Spironolactone 1/3 Hydrate.
Lemos Barbosa TW; Doriguetto AC; Benjamim de Araújo M; Bonfilio R
J Pharm Sci; 2019 Jul; 108(7):2458-2464. PubMed ID: 30853514
[TBL] [Abstract][Full Text] [Related]
17. Dehydration, hydration behavior, and structural analysis of fenoprofen calcium.
Zhu H; Xu J; Varlashkin P; Long S; Kidd C
J Pharm Sci; 2001 Jul; 90(7):845-59. PubMed ID: 11458334
[TBL] [Abstract][Full Text] [Related]
18. Salt screening and characterization for poorly soluble, weak basic compounds: case study albendazole.
Paulekuhn GS; Dressman JB; Saal C
Pharmazie; 2013 Jul; 68(7):555-64. PubMed ID: 23923637
[TBL] [Abstract][Full Text] [Related]
19. Crystal forms of the hydrogen oxalate salt of o-desmethylvenlafaxine.
Dichiarante E; Curzi M; Giaffreda SL; Grepioni F; Maini L; Braga D
J Pharm Pharmacol; 2015 Jun; 67(6):823-9. PubMed ID: 25644936
[TBL] [Abstract][Full Text] [Related]
20. Solid-state phase transitions of AG337, an antitumor agent.
Rastogi S; Zamansky I; Roy S; Tyle P; Suryanarayanan R
Pharm Dev Technol; 1999; 4(4):623-32. PubMed ID: 10578517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
